In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures

Journal of Medical Microbiology

Volumn 56, Issue 6, 2007, Pages 798-802

  Dos Santos, Kênia Valéria ^a   Diniz, Cláudio Galuppo ^a   Coutinho, Simone Cristina ^a   Apolônio, Ana Carolina Morais ^a   De Sousa Gaia, Luciana Geralda ^a   Nicoli, Jacques Robert ^a   Farias, Luiz De Macêdo ^a   De Carvalho, Maria Auxiliadora Roque ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ERTAPENEM; LEDERLE PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG;

AGAR DILUTION METHOD; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTEROIDES FRAGILIS; CULTURE MEDIUM; DILUTION; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; MIXED CELL CULTURE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTEROIDES FRAGILIS; BETA-LACTAMS; COLONY COUNT, MICROBIAL; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PENICILLANIC ACID; PIPERACILLIN; TIME FACTORS;

EID: 34250355599     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.47112-0     Document Type: Article

References (24)

1. Betriu, C., Salso, S., Sanchez, A., Culebras, E., Gȯmez, M., Rodriguez-Avial, I. & Picazo, J. J. (2006). Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins. Int J Antimicrob Agents 28, 1-5.
2. Craig, W. A., Bhavnani, S. M. & Ambrose, P. G. (2004). The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis 50, 229-230.
3. Dela Pena, A. S., Asperger, W., Kockerling, F., Raz, R., Kafka, R., Warren, B., Shivaprakash, M., Vrijens, F., Giezek, H. & other authors (2006). Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. Optimizing Intra-Abdominal Surgery with Invanz (OASIS)-I Study Group. J Gastrointest Surg 10, 567-574.
4. Goldstein, E. J. C. & Snydman, D. R. (2004). Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 53 (Suppl. 2), ii29-ii36.
5. Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. & Tyrrell, K. L. (2000). Comparative in vitro activities of ertapenem (MK-0826) against 1001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 44, 2389-2394.
6. Heilmann, F. (1993). Ampicillin and ampicillin-sulbactam dilution tests with mixed cultures of Bacteroides fragilis, Escherichia coli and Enterococcus. Infection 21, 187-190.
7. Hermsen, E. D., Hovde, I. B., Sprandel, K. A., Rodvold, K. A. & Rotschafer, J. C. (2005). Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 49, 685-689.
8. Jerman, B., Butala, M. & Žgur-Bertok, D. (2005). Sublethal concentrations of ciprofloxacin induce bacteriocin synthesis in Escherichia coli. Antimicrob Agents Chemother 49, 3087-3090.
9. Klepser, M. E., Banevicius, M. A., Quintiliani, R. & Nightingale, C. H. (1996). Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods. Antimicrob Agents Chemother 40, 1941-1944.
10. König, C., Simmen, H. P. & Blaser, J. (1998). Bacterial concentrations in pus and infected peritoneal fluid - implications for bactericidal activity of antibiotics. J Antimicrob Chemother 42, 227-232.
11. Muñoz Bellido, J. L., Muñoz Criado, S., García Garcia, I., Alonso Manzanares, M. A., Gutiérrez Zufiaurre, M. N. & Garcia-Rodrigues, J. A. (1997). In vitro activities of β-lactam-β- lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity. Antimicrob Agents Chemother 41, 2612-2615.
12. NCCLS (2003). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 6th edn. Approved Standard. NCCLS document M7-A6. Wayne, PA: National Committee for Clinical Laboratory Standards.
13. NCCLS (2004). Methods for Antimicrobial Susceptibility Testing for Anaerobic Bacteria, 6th edn. Approved Standard. NCCLS publication M11-A6. Wayne, PA: National Committee for Clinical Laboratory Standards.
14. Pendland, S. L., Jung, R., Messick, C. R., Schriever, C. A. & Patka, J. (2002). In vitro bactericidal activity of piperacillin, gentamicin, and metronidazole in a mixed model containing Escherichia coli, Enterococcus faecalis, and Bacteroides fragilis. Diagn Microbiol Infect Dis 43, 149-156.
15. Perry, C. M. & Markham, A. (1999). Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 57, 805-843.
16. Sader, H. S., Ferreira, A. T., Tosin, I. I., Gales, A. C., Keim, L. S., Carbadillo, J. M., Mello, S. J., Jr & Tavares, W. (1998). Piperacillin/tazobactam: evaluation of its in vitro activity against bacteria isolated in two Brazilian hospitals and an overview of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Braz J Infect Dis 2, 241-255.
17. Schaumann, R., Goldstein, E. J., Forberg, J. & Rodloff, A. C. (2005). Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. J Med Microbiol 54, 749-753.
18. Solomkin, J. S. & Konstantin, U. (2003). Intraabdominal sepsis: newer interventional and antimicrobial therapies for infected necrotizing pancreatitis. Curr Opin Crit Care 9, 424-427.
19. Solomkin, J. S., Yellin, A. E., Rotstein, O. D., Christou, N. V., Dellinger, E. P., Tellado, J. M., Malafaia, O., Fernandez, A., Choe, K. A. & other authors (2003). Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Protocol 017 Study Group. Ann Surg 237, 235-245.
20. Soriano, F., Garcia-Corbeira, P., Ponte, C., Fernandez-Roblas, R. & Gadea, I. (1996). Correlation of pharmacodynamic parameters of five β-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob Agents Chemother 40, 2686-2690.
21. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1997). Bactericidal activity of DU-6859a compared to activities of three quinolones, three β-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology. Antimicrob Agents Chemother 41, 847-849.
22. Stearne, L. E., Kooi, C., Goessens, W. H., Bakker-Woudenberg, I. A. & Gyssens, I. C. (2001). In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique. Antimicrob Agents Chemother 45, 243-251.
23. Thomson, K. S. & Moland, E. S. (2001). Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 45, 3548-3554.
24. Wexler, H. M. (2004). In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 53, ii11-ii21.